Full Press Release Details
Adaptimmune to Report Q1 Financial Results
on Thursday, May 14, 2020
- The Company will also present updated
data at three Congresses -
PHILADELPHIA, PA., and OXFORDSHIRE, U.K., April 29, 2020 (GLOBE
NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in cell therapy to treat cancer, will report financial results
for Q1 2020, before the U.S. markets open on Thursday, May 14, 2020.
Following the announcement, the Company will host a live teleconference and webcast at 8:00 a.m. EDT (1:00
p.m. BST) on the same day (details below).
press release and the live webcast of the conference call will be available in the investor section of Adaptimmune's corporate
website at www.adaptimmune.com. An archive will be available after the call at the same address.
participate in the live conference call, please dial (833) 652-5917
(U.S. or Canada) or +1 (430) 775-1624
(International). After placing the call, please
ask to be joined into the Adaptimmune conference call and provide the confirmation code (8635337).
Upcoming Congress Presentations
Society of Gene and Cell Therapy (ASGCT) Annual Meeting
Society of Clinical Oncology (ASCO) Annual Meeting
European Association
for the Study of the Liver (EASL) International Liver Congress (ILC) 2020
Adaptimmune is a clinical-stage biopharmaceutical company focused
on the development of novel cancer immunotherapy products for people with cancer. The Company's unique SPEAR (Specific
Peptide Enhanced Affinity Receptor) T-cell platform enables the engineering of T-cells to target and destroy cancer across multiple
Forward-Looking Statements
This release contains "forward-looking statements"
within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA). These forward-looking statements involve certain
risks and uncertainties. Such risks and uncertainties could cause our actual results to differ materially from those indicated
by such forward-looking statements, and include, without limitation: the success, cost and timing of our product development activities
and clinical trials and our ability to successfully advance our TCR therapeutic candidates through the regulatory and commercialization
processes. For a further description of the risks and uncertainties that could cause our actual results to differ materially from
those expressed in these forward-looking statements, as well as risks relating to our business in general, we refer you to our
Annual Report on Form 10-K filed with the SEC on February 27, 2020, and our other SEC filings. The forward-looking statements contained
in this press release speak only as of the date the statements were made and we do not undertake any obligation to update such
forward-looking statements to reflect subsequent events or circumstances.
Adaptimmune Contacts:
S bastien Desprez - VP, Communications and Investor
Juli P. Miller, Ph.D. - Senior Director, Investor Relations